NeuroSense Therapeutics Ltd.
NRSNHealthcareNASDAQBiotechnology · Last scanned Oct 22, 2026
Scan Results
Daily timeframeNeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and. The company carries a $4.9M market cap, placing it firmly in the micro-cap category. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease.
Market Cap
$4.9M
Beta
1.64
P/E (TTM)
—
P/E (Fwd)
-0.55
EPS (TTM)
$-50.45
EPS (Fwd)
$-4.67
ROE
-2175.0%
ROA
-247.3%
Cash
$166,000
Total Debt
$170,000
Free CF
-$3.9M
52W Change
-89.0%
Annual Financials
Cash vs Debt
Where NRSN stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, NRSN finished 77.77% below its 150-day moving average ($12.01) and 80.40% below its 200-day moving average ($13.62). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NRSN overbought or oversold?
At the October 20, 2026 close, NRSN's RSI(14) was 12.0, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $166K in cash, though total debt stands at $170K. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$3.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -2175.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta above 1.5, NRSN tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing NRSN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.